Cargando…
No clinically relevant removal of meropenem by cytokine adsorber CytoSorb(®) in critically ill patients with sepsis or septic shock
Autores principales: | Liebchen, Uwe, Scharf, Christina, Zoller, Michael, Weinelt, Ferdinand, Kloft, Charlotte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550492/ https://www.ncbi.nlm.nih.gov/pubmed/34519848 http://dx.doi.org/10.1007/s00134-021-06487-y |
Ejemplares similares
-
Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
por: Scharf, Christina, et al.
Publicado: (2022) -
Experience with hemoadsorption (CytoSorb(®)) in the management of septic shock patients
por: Mehta, Yatin, et al.
Publicado: (2020) -
CytoSorb® Hemoadsorption as a Promising Tool to Handle COVID-19-Induced Cytokine Storm
por: Acevedo, Alice-Christin, et al.
Publicado: (2021) -
Use of CytoSorb in Traumatic Amputation of the Forearm and Severe Septic Shock
por: Steltzer, Heinz, et al.
Publicado: (2017) -
Can the cytokine adsorber CytoSorb(®) help to mitigate cytokine storm and reduce mortality in critically ill patients? A propensity score matching analysis
por: Scharf, Christina, et al.
Publicado: (2021)